

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

DEC 08 2010

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/627,358
Filing Date	July 23, 2003
First Named Inventor	Peter Migaly
Art Unit	Art Unit 1614
Examiner Name	Eric Olson
Attorney Docket Number	--

Sheet 1

of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓ 1a	Texas Algorithm July 2004 Arch Gen Psych p671 <a href="http://archpsyc.ama-assn.org/cgi/content/abstract/61/7/669">http://archpsyc.ama-assn.org/cgi/content/abstract/61/7/669</a> - see within the reply and next:	
	✓ 1b	Clinical Results for Patients With Major Depressive Disorder in the Texas Medication Algorithm Project M. H. Trivedi; A. J. et al. Arch Gen Psychiatry. 2004;61:669-680.	
	2a	Berlin Algorithm Project -in Aldi 2003 [listed below under #2 and at page 6 of our reply]	
	2b	Algorithm Study of the German Research Network on Depression -in Aldi 2003 [listed below under #2 and at page 7 of our reply]	
	2c	STAR*D -(stepwise treatment procedures in depression) -NIMH funded study -in Aldi 2003 [listed below under #2 and at page 8 of our reply]	
	✓ 2	Aldi, M. et al Algorithms for optimizing the treatment of depression: Making the right decisions at the right time. Pharmacopsychiatry 2003; 36 Suppl 3: S222-S229.	
	2d	see also: <a href="http://www.charite.de/psychiatrie/publikationen/2003.html">http://www.charite.de/psychiatrie/publikationen/2003.html</a>	
	✓ 3	Interview with Russel Katz director of neuropharmacological drug products at the FDA - Tribune Review March 23 2004 (Antidepressants...)	
	✓ 4	Interview with Robert Temple director of FDA's Office of Medical Policy - Pittsburgh Post-Gazette December 14 2006 (FDA may expand alert...)	
	5	see also citations from the utility - revisited in this reply to the OA of December 2010 at pages 2-3.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.